Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05105958 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis

Study acronym: TIDALS
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 28, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Lead sponsor: University Hospital, Geneva to University of Zurich Collaborators revised (4)v3 Show 1 more changeShow less
    • Collaborators revised (4)

    See this version in full on ClinicalTrials.gov ↗

  2. Primary completion date: Dec 1, 2023 to Dec 1, 2025 Start date: Dec 1, 2021 to Dec 1, 2025 · Completion date: Mar 1, 2024 to Mar 1, 2026v2 Show 2 more changesShow less
    • Start date: Dec 1, 2021 to Dec 1, 2025
    • Completion date: Mar 1, 2024 to Mar 1, 2026
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Zurich
157 trials monitored
See 3 trials at risk
ALS
387 trials monitored
See 18 trials at risk
Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative condition, mainly characterized by progressive weakness and wasting of the limbs, the respiratory and bulbar muscles. Respiratory insufficiency leads to a fatal outcome after a mean diseases duration of only three to five years. The disease is characterized by pathological accumulations of a protein called TDP-43, which can be found large cortical and sub-cortical areas of post-mortem ALS brains. No causal treatment for this condition is known to date, and there is a large unmet need to develop new strategies in order to halt or slow down its progression. The aim of this study is to test the safety and tolerability of Tideglusib, a treatment that is already in clinical trials for other neuromuscular conditions, in patients with ALS. It is assumed that this drug may have a significant therapeutic benefit in this population due to his mode of action: In the ALS mouse model, Tideglusib decreases significantly the amount of accumulated TDP-43 proteins within the cells.
Trial Details
NCT Number NCT05105958
Lead Sponsor University of Zurich
Collaborators: University of Lausanne Hospitals, University of Bern, Cantonal Hospital of St. Gallen, University Hospital, Geneva
Conditions Amyotrophic Lateral Sclerosis
Enrollment 98 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov